Reddit Posts
Top 8 Breakout Candidates for the week of 8/30
Mentions
All of them follow the same trend - EDIT, CRBU, NTLA, PACB The "smaller" CRISPR stocks hit higher percentage gains but take bigger beatings, too. The ones I'd be interested in optioning would be EDIT and CRBU. But I'd rather buy the shares outright TBH
CRBU, IXHL, OPEN I only have a position in CRBU fwiw
If you are looking for a serious answer, my money would be on one of the CRISPr gene-editing companies. EDIT, CRBU, BEAM, NTLX, CRSP. Some have already begun utilizing their sequencing to save lives. Others are beginning to patent additional sequencing. I think the BIG one will come when a company realizes how to edit agricultural genetic code to utilize less nutrients, and grow in harsher climates.
I believe CRBU has a great potential with its allogeneic CAR-T therapies for hematological cancers and autoimmune diseases and its current valuation which is lower than peers.
CRBU has gone from $1.85/share in the past couple of months to nearly $3 now. A good option to take a look at.
CRISPR Therapeutics and Vertex Pharma. I have about three percent of my total portfolio in gene editing stocks (CRSP/VRTX/NTLA/CRBU). Very risky investments IMO, but I'm planning to hold them all for decades. In the case of CRSP/VRTX, my time horizon is forever.
is this stock better than CRBU? maybe i should cut down research time on CRBU and focus on this IMTX
Guys lets push $CRBU to the moon, do it for me
Guys can we get $CRBU up, I’m broke
$CRBU is going to go up pretty fast
I have a boat load of CRSP/CRBU shares in my IRA but other than that no
Crispr stocks: NTLA, EDIT, CRSP, BEAM, CRBU (maybe wait for a bit more drop on this one), also RIVN
https://preview.redd.it/3nfk4ntdthpc1.jpeg?width=1284&format=pjpg&auto=webp&s=3844304a00c093b6dbb962846e428c4cb86acfbd $CRBU insiders are loading up great chance to buy cheap
$CRBU, do it now before its too late. Long term option call hold in expire in October just watch
No I’m holding all major players but at different position sizes based on my confidence in the company, CRSP is my largest position by far but that’s also because it’s grown a lot recently, followed by NTLA, BEAM, VERV, CRBU, PRME, EDIT, GRPH
CRBU, they have a crucial clinical trial result coming out in March.
10$ Long call on $CRBU expiring in Oct. the stock is up 36% since Jan. Option up 17% today. 👌👌👌🔥
10$ Long call on $CRBU expiring in Oct. the stock is up 36% since Jan. Option up 17% today. Trust this one boys👍
Biotech are like lottery tickets, find one with something that hasn’t been approved yet and buy it low, and wait. You either win the morning they get fda approval for whatever drug, or they dilute/RS you into oblivion. I’m holding DARE, ARDX, and XLO, and watching CRBU, CARM, and PLX.
Acknowledged! Thanks for the write-up. I have a large bagholder position in CRSP too. I drank the Crispr tech kool aid and am also bagholding EDIT and CRBU. I'm not in MRNA anymore but it's always on my watchlist. I bought it in the mid 20s at the start of the pandemic and sold when it doubled, which was very painful as I watched it 10x after I sold. If it falls back near to my sell price I might get back in.
If these biotech companies come out with good clinical results or interest comes back to biotechs, these biotechs are an easy 2 to 3x. I am personally bullish on CRBU, Dr Jeniffer Doudna (inventor of Crispr) is cofounder and they have made many complete remissions from cancer in Phase1 trial which is why Pfizer ended up buying 25m$ equity in it.
Buy more CRBU. Always.
Here is CRBU’s latest presentation. https://investor.cariboubio.com/static-files/3168b9f6-48dd-4e44-8103-df5ff9013b6b
ALLO is a good bet and so is Caribou Biosciences (CRBU). They had many remissions in Phase 1 Trials and looks promising for Car-T cell therapy.
You could find a discounted stock like CRBU who just has Pfizer make a significant investment in their cancer/lymphoma genetic based research. I picked up a few units today for my portfolio.
I'm invested in CRBU, that's why I asked.
What do you think about their investment into Caribou Biosciences (CRBU)?
The only good thing about PFE is that they just invested in gene editor CRBU.
$CRBU bag holders Lmao 
$CRBU Crash will be awesome to see
$CRBU will crash and leave Bag holders with losses
$CRBU Crash incoming Lmao
💰💰💰Get new runners in our app! #premarket #watchlist 07/6 $MULN - Announces $25 Million Stock Buyback Program (+66%), $AKU - no news + big volume (+30%) $CRBU - Announces $25 Million Equity Investment from Pfizer (+21%), $KZIA - awarded Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) (+18%) https://preview.redd.it/x8hbkiuubcab1.jpeg?width=576&format=pjpg&auto=webp&v=enabled&s=5e8cb6dcec140e8d7a6c2981d695b7cc16a5ab06
💰💰💰Get new runners! #premarket #watchlist 07/6 $MULN - Announces $25 Million Stock Buyback Program (+66%), $AKU - no news + big volume (+30%) $CRBU - Announces $25 Million Equity Investment from Pfizer (+21%), $KZIA - awarded Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) (+18%) https://preview.redd.it/dbkb6qksbcab1.jpeg?width=576&format=pjpg&auto=webp&v=enabled&s=0b4c0de621a1c4ac5f30168f782051ff28652279
30k as an emergency fund. The rest I would take a chance and split between two genomics stocks. Probably CRBU and CRSP. If that works out I would sell at some point and dump it all into VOO or SPY on pullbacks and sell calls
I have 1/3rd of my portfolio allocated for micro and small caps that have the potential to 10x or more. These are the high risk, not yet profitable companies with huge upside potential. So far most of mine are green energy and biotech related \-SAVA (Alzheimer's stage 3 drug) \-CRBU ( crisper genome cell therapies ) \-EOSE (zinc battery grid storage, lithium alternative) \-EXROF (EV efficient car parts) \-EEMMF (lithium) Enphase was previously on this list when I started buying at $15 and it became my first 1,000% gain. Looking for more ideas... What are your top 2 picks and why?
I have an undergraduate degree in microbiology, but I’m absolutely incapable of explaining it. I just think gene editing will be part of the future of medicine and I think one of the few big CRISPR companies will either make money or get bought. I own EDIT and CRBU.
LABU in general. CRBU is my most regarded play.
They are crushing it and are relatively safe. Small caps have so much more risk and less reputable boards have a lot of spam pumpers. With that said, I do think the market “bottomed” from highs last November. Interest hikes are prices in. There are a lot of exciting under 1 b companies that ipo’d high, have cool tech, and a long runway. I like cell and gene therapy companies like CRBU and SANA. There is lose everything or 10x in a decade potential there
I chose GNOM over ARKG when I decided I didn't have time to track my CRISPR stocks (CRSP, NTLA, BEAM, CRBU) individually. It has a lower cost basis than ARKG, a larger percent of it's top 10 holdings directly in gene-editing companies (14.66% to 12.42%), and I just don't trust Cathie Wood. For example, she has Teledoc as the 4th largest holding in ARKG, which is allegedly a "Genomic Revolution" ETF. How does Teledoc fit? I **love** UiPath, but why is an RPA SaaS company almost 2% of a genomics ETF? Why is there $300,000 in ONEM, a primary care company? Bizarre.
Anyone here have CRBU? Looks good but can't understand the low volume rn
SANA and CRBU... small cap bio-techs took too much of a beating after getting healthy IPOs, and are now set with strong balance sheets to rock
GNOM because time matters now that I have a baby and following the companies in my CRISPR basket (CRSP, NTLA, BEAM, and CRBU) wasn't worth the time anymore but I still wanted skin in the gene-editing game.
Caribou biosciences (CRBU). They’re the Tesla of allogeneic therapy.
I own BEAM, CRBU, CRSP and NTLA. EDIT is also another popular one. They'll be profitable if/when they have a drug/treatment come to market. However, that is a long ways away. The total cost basis for my basket of 4 stocks equals the cost basis of one of my normal individual stocks. Very high reward with a very high risk. If you want a better grasp on the biotechnology and the possibilities, read The Code Breaker. One of my favorite books that I read last year. Entertaining and not overly complicated when explaining CRISPR and gene-editing.
Preach. I hold CRSP, CRBU, BEAM, and NTLA in my IRA.
As of 3/31/22: * NTLA is 38% * BEAM is 27% * CRSP is 26% * CRBU is 10% They all started with the same total $ cost basis though. CRBU has... not been well received by investors lol
Same. I think biotech at large has trended down as people sought to get into energy and commodity focused stocks and away from growth plays. Probably a good time to plus up my CRBU allocation using some of my gains from those sectors.
* NNOX. If they and their x-ray tech doesn't turn out to be a complete and utter fraud, they will revolutionize x-rays. Could easily see them being a $62B MC. * LLNW if management ever gets their shit together. * BGRY if they can execute. * Any of the CRISPR companies (CRBU, CRSP, EDIT, NTLA, BEAM, etc.)
Hope you're right about the CRSPR tech. My bags are heavy with CRSP, EDIT, and CRBU.
Caribou Biosciences, CRBU, a front runner in Gene editing crispr technology
Don't go! I'm holding CRBU and want to hear (read) more!
…and when she’s at her most desperate, I’ll tip her about my deep value propositions in RKLY, CRBU, & ASTR
Ur picks are in that vast gap between big tech and no rev tech, which is an area we like to avoid at the moment. They’ve all hit massive valuations and are bearing the brunt of the sell off (and could continue to do so). Prefer barbelling between the big tech and no rev super growth moonshots. Lots of these firms raised cash last year and have incredibly cheap enterprise values from the sell-off. For the moonshots, own shares or calls in RKLY, CRBU, IONQ, ASTR, & PACB. RKLY has the best near term price catalysts due to a med device product launch this year, potentially with Medtronic (a VC stage investor). And the possibility of being the key feature upgrade in this or next year’s Apple Watch (Apple was disclosed as a client during the listing).
Crisper stocks....NTLA, BEAM, EDIT, CRBU Fintech .... wPLCF, paypal, sq
I bought SOFI every day for a couple weeks ending last week - either selling puts that got filled, buying shares outright, or buying July $12.5 and $15 calls. I’ve averaged down on EDIT and CRBU and I’ll probably do more of that to hold very long term until that sector recovers one day.
Does anyone else buy CRISPR stocks? I’ve been buying EDIT and CRBU waiting for another good development that lifts all CRISPR stocks, but they are really shitting the bed. EDIT is at $22 from a high of $84 and CRBU is at $12 from a high of $32. It’s crazy.
I do! I somewhat work in the space and so I really like what these companies are doing. Other ones I like are 1. ALLO 2. CRBU 3. FATE 4. EDIT. That said, I think this is a good time to get in these stocks. I personally don’t really see EDIT doing anything super crazy this year, but I can see it doing okay and being worth holding for a bit. That’s what I plan on doing with it. For transparency, I actually only hold 3 positions right now: 1. 120 shares of NVDA 2. 143 shades of SAVA I bought this morning for just barely under $7k 3. 1 CRSP call I bought on margin for $130 for a $74 price prediction (still new to options, not sure what the proper terminology is here) that expires this Friday. I’m currently down about $90 on that so… lol. But! I’d love it if these prices stayed like this for a couple of months so I can save up some more money and get into them hahaha. I’d legit love to own like, a minimum of 100 shares of each.
>When we trade, we’re actively entering and exiting with shorter times holdings. How short is "short" here? >Traders don’t make one trade that materializes and stop. Some do. If you hit your financial goal I don't see why you wouldn't. Remember, this is retail, not II. >They need to place additional trades throughout the year, increasing their risk exposure. This doesn't make sense. If I trade 4 times a year on earnings for a specific company in 5 week intervals I have much less market risk exposure than someone who trades just 1 LEAP and holds it the entire year. If I am not in the market I am not suffering market risk. >Investing is far more suitable for most wishing to speculate in the markets. Why? Because it tends to capitalize on positive long term market drift. Picking individual stocks can be tricky but you’ll still find far more successful folks that invest than trade. This is completely backwards. The entire reason why most people should invest in index funds is because investing in single stocks for 5+ years is actually really risky and requires an incredible amount of knowledge and awareness. Market drift does not apply as strongly to individual stocks over longer periods of time because sector clustering breaks down etc. as real performance is measured. Voting Machine vs. Weighing Machine etc. >As for your example on new traders getting lucky, their ignorance isn’t what’s helping them. It’s their small sample size. **If a naive trader continued to trade, their performance will begin to concentrate around a mean**. Smaller samples mixed with luck produce outliers and skew. Give it time. So the problem with this is actually two fold. 1. The mean itself is not indicative of skill. 2. The general management of this mean via any number of formulas can be manipulated. To be simple people will almost always pick and choose the metric that flatters them the most but will also almost never express metrics that don't. For instance if I had to look at your "win rate" versus your "CAGR" what would I find? If I judged you on your Sharpe vs. your ROI what would I find? You'll state whichever is most flattering but likely won't share the full data, i.e. how many trades were in this data, the average range of real return, the volatility and risk, the beta, etc. I pose that it's the ignorance that helps *because* people are more likely to simply go with what they know. Everyone knows what MSFT and AAPL are. No one knows the obscure CRBU biotech company. Here's a set of graphs of data regarding D-K that matter. [Specifically figure 4](https://graphpaperdiaries.com/2017/08/20/the-real-dunning-kruger-graph/). In essence I am saying that one's innocence and ignorance guides them towards general knowledge; the experts think they are average and the beginners think they are also average so when you try to sprinkle in FinViz as a tool and say, "You, too, can use this!" you end up actually poisoning the well because the person has no idea how bad off they are *and* people have a [humans are insane and really well built to detect imaginary patterns](https://cocosci.princeton.edu/tom/papers/hard.pdf). So, anyone who takes your advice, even if they have been doing it for a decade, may not understand that the real results may not reflect a genuine function. The mean trend is not indicative of ability in a system which there is variance on variance on variance. Yes, three levels of actual randomness exist in trading, at least three anyway, and that means that you cannot determine, with clarity, skill vs. luck and sound *p-values*. TL;DR: You have zero idea how good you are at short-term trading because it's noisy. That is incredibly convenient to sell the idea that your metrics, esp. your best ones, are valid. Also, I've been a researcher for ... a decade now? So a little over 8 years as of this time. Not that it matters; I definitely wouldn't pose that I am more clever than a trader who started working at Goldman Sachs only 2 years ago. That's top notch mentorship.
CRISPR stocks aren’t following to drop for some reason. I’m just holding CRBU right now.
Could be $CRSP, $EDIT (editas), or $CRBU (caribou bioscience). I wouldn't go all in one just one of the CRISPR tech stocks because you don't know which may break out first.
Since I was moving some of my money from existing tech, to future tech, it looked like the CRISPR technology seemed promising. (And I wanted to diversify away from the current software/ electronics tech). My timeframe for my crisper stocks (NTLA, BEAM, EDIT, CRBU) is a minimum of 10 years. Maybe one of them will do something amazing. I would recommend dollar cost averaging into these stocks (very volatile at this time), but I think this bio tech will lead to some amazing discoveries.
CRBU is a risky CRISPR play. Could pay off bigly in the next 10 years. Could also get delisted.
There is a massive bubble in Crispr tech and it's popping or, will be. I suggest checking out these experts on twitter: @biotech2k1 or @natharooni to start. My bet in this space is on Caribou Bioscience ticker: CRBU which is a company started and ran by Jennifer Doudna (mentioned on this thread). They are exploring iPSCs as a delivery mechanism too which handles a major problem discovered with CRSP's latest data read-outs (durability). There's a lot to read on the topic, including who holds what patents in this tech too.
I just want to share that I was clearly battling with Cathie Wood over CRBU shares this week and her sells ripped right through my stop-loss, which was rejected... and she drank my milkshake. It was one of my proudest moments as a trader just to be in that battle, you know?
I know you can rage, CRBU... and it's power hour.
Anyone else running with CRBU? This one has legs... and maybe wings.
lets fucking GOOO IRNT and CRBU cybersec and CRISPR saving my portfolio
IRNT and CRBU are saving my ass today
Anyone here genomics gang? $CRSP $NTLA $EDIT $BEAM $CRBU 🧬🧬✌️🚀🚀
I really thought that CRBU would reach $35 this week... which means it's still undervalued.
...If you liked buying CRBU at $32.50, you should love buying it at $30...
This is the only dip on CRBU that you'll get.
As I understand it, institutions will just be scrambling to buy CRBU for the next month.
I'd rather have the markets open today than another day off, to be honest. If CRBU can reach and hold $35 this week, I think it can hit $50 by the time EDIT reports data at the end of the month.
I'm guessing Asian investors are doing their due diligence on CRBU today and putting in massive stock orders for Tuesday morning.
This long weekend is all about people discovering that CRBU has next-level CRISPR tech and talking about CRBU at parties as the gene-editing stock they somehow missed.
This long weekend is all about people discovering that CRBU has next-level CRISPR tech and talking about CRBU at parties as the gene-editing stock they somehow missed.
CRBU with the strong close... and it'll be even higher on Tuesday morning.